Ticker: GRTX

Galera Therapeutics, Inc. (NASDAQ: GRTX) - quick internal read: the company has effectively pivoted after a failed FDA resubmission path for avasopasem, completed the acquisition of Nova Pharmaceuticals (tilarginine/pan‑NOS program), sharply reduced headcount and is operating with minimal staff w...

**Galera Therapeutics, Inc.** (NASDAQ: GRTX) has reported its quarterly financial results for the period ending March 31, 2025. Below are the key highlights and insights derived from the income statement and company information. Positive Aspects: Significant reduction in net loss from $4.38 mill...